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Summary
Background Infections have been hypothesised to increase the risk of dementia. Existing studies have included a 
narrow range of infectious diseases, relied on short follow-up periods, and provided little evidence for whether the 
increased risk is limited to specific dementia subtypes or attributable to specific microbes rather than infection 
burden. We aimed to compare the risk of Alzheimer’s disease and other dementias across a wide range of hospital-
treated bacterial and viral infections in two large cohorts with long follow-up periods.
Methods In this large, multicohort, observational study, the analysis was based on a primary cohort consisting of 
pooled individual-level data from three prospective cohort studies in Finland (the Finnish Public Sector study, the 
Health and Social Support study, and the Still Working study) and an independent replication cohort from the UK 
Biobank. Community-dwelling adults (≥18 years) with no dementia at study entry were included. Follow-up was until 
Dec 31, 2012, in the Health and Social Support study, Dec 31, 2016, in the public sector study and the Still Working 
study, and Feb 7, 2018, in the replication cohort. Through record linkage to national hospital inpatient registers, we 
ascertained exposure to 925 infectious diseases (using the International Classification of Diseases 10th Revision 
codes) before dementia onset, and identified incident dementia from hospital records, medication reimbursement 
entitlements, and death certificates. Hazard ratios (HRs) for the associations of each infectious disease or disease 
group (index infection) with incident dementia were assessed by use of Cox proportional hazards models. We then 
repeated the analysis after excluding incident dementia cases that occurred during the first 10 years after initial 
hospitalisation due to the index infection.
Findings From March 1, 1986, to Jan 1, 2005, 260 490 people were included in the primary cohort, and from Dec 19, 2006, 
to Oct 1, 2010, 485 708 people were included in the replication cohort. In the primary cohort analysis based on 
3 947 046 person-years at risk (median follow-up 15·4 years [IQR 9·8–21·0]), 77 108 participants had at least one 
hospital-treated infection before dementia onset and 2768 developed dementia. Hospitalisation for any infectious 
disease was associated with increased dementia risk in the primary cohort (adjusted HR [aHR] 1·48 [95% CI 
1·37–1·60]) and replication cohort (2·60 [2·38-2·83]). The association remained when analyses were restricted to new 
dementia cases that occurred more than 10 years after infection (aHR 1·22 [95% CI 1·09–1·36] in the primary cohort, 
the replication cohort had insufficient follow-up data for this analysis), and when comorbidities and other dementia 
risk factors were considered. There was evidence of a dose-response association between the number of episodes of 
hospital-treated infections and dementia risk in both cohorts (ptrend=0·0007). Although the greatest dementia risk was 
seen for central nervous system (CNS) infections versus no infection (aHR 3·01 [95% CI 2·07–4·37]), excess risk was 
also evident for extra-CNS infections (1·47 [1·36–1·59]). Although we found little difference in the infection-dementia 
association by type of infection, associations were stronger for vascular dementia than for Alzheimer’s disease 
(aHR 2·09 [95% CI 1·59–2·75] versus aHR 1·20 [1·08–1·33] in the primary cohort and aHR 3·28 [2·65–4·04] versus 
aHR 1·80 [1·53–2·13] in the replication cohort).
Interpretation Severe infections requiring hospital treatment are associated with long-term increased risk of dementia, 
including vascular dementia and Alzheimer’s disease. This association is not limited to CNS infections, suggesting 
that systemic effects are sufficient to affect the brain. The absence of infection specificity combined with evidence of 
dose-response relationships between infectious disease burden and dementia risk support the hypothesis that 
increased dementia risk is driven by general inflammation rather than specific microbes.
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Although dementia is the fifth leading cause of death 
worldwide, poor understanding of its aetiology hampers 
prevention.1 Several lines of research suggest a role 
for inflammation and infectious disease.2–4 Genes that 
predispose individuals to dementia are involved in 
inflammatory pathways;2 systemic inflammation has 
been associated with acce lerated cognitive decline and 
dementia in prospective studies;5–7 and associations 
between infection and dementia have been found in 
several independent cohorts.8–13
Alternative explanations of these findings exist. The 
germ hypothesis, supported by animal models of herpes 
simplex virus type 1,14,15 proposes that specific microbes 
can cause Alzheimer’s disease;3,4,16 however, there is little, 
inconsistent evidence for herpes viruses in the human 
brain.3,16–19 An extension to the germ hypothesis—ie, the 
antimicrobial protection model of Alzheimer’s disease—
suggests that accumulation of amyloid β (a diagnostic 
biomarker of Alzheimer’s disease and an antimicrobial 
peptide) is a physiological response against invading 
pathogens.20 A broader inflammation hypothesis 
suggests that systemic inflammation more generally 
contributes to the development of Alzheimer’s disease 
and other dementias.3,16 Consistent with this explanation, 
people with severe acute events, such as sepsis and 
delirium, have an increased risk of cognitive decline,7,21 
and many infectious diseases (eg, pneumonia, osteo­
myelitis, cellulitis, urinary tract infections, and herpes 
virus infections) are associated with higher subsequent 
risk of dementia.8–10,12,22
The narrow focus of most human studies has not 
provided strong evidence for whether certain infections—
or factors specific to the microbes that cause these 
infections—are linked to Alzheimer’s disease or other 
dementias, or whether the association between infection 
and dementia is driven by general inflammation and, 
thus, infectious diseases in general. A further limitation 
of current evidence is presented by studies with short 
follow­up periods. Given the long preclinical phase of 
Research in context
Evidence before this study
Infectious diseases are hypothesised to be involved in the 
aetiology of dementia, but evidence from studies that 
simultaneously examine a wide range of infections is 
inadequate. We searched PubMed on April 2, 2020, for 
observational studies and systematic reviews using the search 
terms “((Alzheimer* OR dementia)” AND “infectio*” AND 
“(systematic[sb]) OR (Observational Study[ptyp]))” without 
restrictions on language or publication date. In observational 
studies, infectious diseases in general, specific bacterial 
infections (eg, sepsis, pneumonia, osteomyelitis, urinary tract 
infection, and cellulitis), and viral infections (hepatitis C, HIV) 
have been linked to an increased risk of dementia. Additionally, 
there was suggestive evidence for associations of herpes virus 
infections, Toxoplasma gondii infection, and poor oral health 
with dementia. No large-scale studies assessed a wide range of 
infectious diseases in a single analytical setting with adequate 
control for potential ascertainment bias and reverse causation 
resulting from the effects of preclinical dementia on 
susceptibility to infectious diseases.
Added value of this study
In this multicohort study, we focused on hospital-treated 
infections to compare effect sizes across types of infection. 
The primary analysis was based on individual-level data from 
three Finnish cohort studies and included 260 490 dementia-
free community-dwelling individuals with a median follow-up 
of 15 years. The main findings were replicated in an independent 
cohort of 485 708 individuals from UK Biobank (median 
follow-up 7·7 years). We tracked 925 infectious diseases before 
dementia onset from national hospital inpatient records. 
Infectious disease hospitalisations were associated with a 
1·5-fold increased risk of dementia, with infections occurring 
more than 10 years before dementia onset also associated with 
excess risk. We observed a dose-response relationship between 
infection burden (number of infection episodes over time and 
number of co-occurring infections) and dementia (ptrend=0·0007). 
Although the greatest risk was observed for infections of the CNS 
(adjusted hazard ratio [aHR] 3·01), extra-CNS infections were 
also associated with dementia (aHR 1·47). Dementia risk did not 
vary substantially by type of infection: bacterial versus viral 
(aHR 1·50 vs 1·70); bacterial infections with sepsis versus without 
sepsis, extracellular versus intracellular, Gram-positive versus 
Gram-negative; or herpes virus infection versus other persistent 
viral infections, although associations with acute viral infections 
were weaker. Both bacterial and viral infections were more 
strongly related to vascular dementia than Alzheimer’s disease.
Implications of all the available evidence
Infectious diseases are associated with increased long-term risk 
of dementia, including Alzheimer’s disease, the strongest risk 
being for vascular dementia. This increased risk is not limited to 
CNS infections, suggesting that systemic infections are 
sufficient to affect the brain. Analyses stratified by severity of 
infection, location (extracellular vs intracellular) or Gram stain 
of bacteria, and type of virus provide no support for the 
hypothesis that specific pathogens underlie the infection-
dementia association. The dose-response relationship observed 
between the number of episodes of hospital-treated infection 
and dementia suggests the increased risk might be attributable 
to general inflammation. These findings show the potentially 
important role of severe infections in the cause of Alzheimer’s 
disease and other dementias. Further studies should determine 
whether strategies to improve infection control could prevent 
or delay dementia.
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dementia, such study designs can lead to inflated 
effect estimates because of reverse causation (systemic 
changes related to preclinical dementia increase 
susceptibility to infection) and ascertainment bias (an 
infectious disease diagnosis increases the likelihood of a 
dementia diagnosis).3,8,19 Long follow­up periods 
minimise these biases and help to determine whether 
infections trigger the early stages of neuro degeneration.
In this large­scale study, we systematically assessed the 
short­term and long­term dementia risk associated with 
infectious diseases in general and with specific types of 
infectious disease in two large cohorts. We addressed 
this aim by attempting to answer the following questions: 
is the association between infectious diseases and 
dementia specific to certain microbes or dementia 
subtypes, or attri butable to inflammation and dementias 
more generally; is systemic inflammation sufficient to 
affect the brain or is central nervous system (CNS) 
involvement necessary for an infection to increase 
dementia risk; and are infectious diseases associated 
with dementia long­term when the likelihood for reverse 
causation and ascertainment bias is reduced.
Methods
Study design and population
In this large, multicohort, observational study, the 
analysis was based on a primary cohort consisting of 
pooled individual­level data from three harmonised 
prospective cohort studies linked to national health 
registries in Finland (the Finnish Public Sector study, the 
Health and Social Support study, and the Still Working 
study) and an independent replication cohort from the 
UK Biobank. Full study details and a flowchart describing 
participant selection are provided in the appendix (pp 4–8). 
Briefly, we included adult individuals (≥18 years) who 
were free of known dementia on study entry. Follow­up 
was until Dec 31, 2012, in the Health and Social Support 
study, Dec 31, 2016 in the Finnish Public Sector study 
and the Still Working study, and Feb 7, 2018, in the 
replication cohort.
Data collection and analysis in the primary cohort were 
approved by the ethics committees of the Helsinki and 
Uusimaa Hospital District, Turku University Central 
Hospital, and the Finnish Institute of Occupational 
Health. The replication analysis was done under a 
generic approval from the National Health Service 
National Research Ethics Service (11/NW/0382).
Exposure to hospital-treated infectious diseases
We linked participants of the primary cohort to the Care 
Register for Health Care (Finland). Participants of the 
replication cohort were linked to hospital admission data 
from Hospital Episode Statistics–Admitted Patient Care 
(England), Scottish Morbidity Records–General/Acute 
Inpatient and Day Case Admissions (Scotland), and 
Patient Episode Database for Wales. We retrieved primary 
and secondary diagnoses of infectious disease from 
inpatient hospital discharge information from these 
registries using the International Classification of 
Diseases 10th Revision (ICD­10) codes. Diagnostic codes 
for the 8th and 9th revisions (ICD­8 and ICD­9) were 
converted into ICD­10 codes.
For the primary analysis, we classified hospital­treated 
infectious diseases hierarchically to reflect the type 
of pathogen and severity of infection (figure 1). 
Level 1 includes all infectious diseases—ie, a total of 
925 ICD­10 codes—except for mild upper respiratory 
tract infections. At level 2, infectious diseases are 
divided into bacterial, viral, parasitic, or fungal 
infections. In level 3, we further classified bacterial 
infections to reflect properties of the infection and 
pathogen: disease invasiveness and severity ([potentially] 
invasive vs [mostly] localised, and with sepsis vs without 
sepsis); bacterial location and related adaptive immune 
responses (extracellular vs obligate or facultative 
intracellular [extracellular bacteria tend to trigger type 17 
T­helper responses, intracellular bacteria and viruses 
tend to trigger type 1 T­helper responses]);23 and cell 
wall structure (Gram­positive vs Gram­negative bacteria 
vs mycobacteria vs mycoplasma [lipopolysaccharides 
produced by Gram­negative bacteria strongly stimulate 
the immune system]).24 Classifications of bacterial 
location and cell wall structure were based only on 
ICD­10 codes that defined the causative microorganism 
unambiguously (eg, shigellosis, legionnaires disease, 
pneumonia due to Haemophilus influenzae). Examples 
of invasive bacterial infections included appendicitis, 
pneumonia, and pyelo nephritis; and localised bacterial 
infections included gastroenteritis, tonsillitis, and 
cystitis. We also classified viral infections into acute 
infections typically eradicated by the immune system, 
herpes virus infections that persist in the body after 
primary infection, and other persistent viral infections 
such as HIV. Mycobacterial, mycoplasma, parasitic, and 
fungal infections were too rare to be analysed separately, 
but they were included in the analyses of the broader 
categories of infections to which they belonged.
In additional analyses, we further divided infections 
into CNS versus extra­CNS infections; infections 
predisposed towards entering the CNS versus not 
predisposed; and chronic versus acute infections. The 
appendix (pp 29–193) provides the ICD codes for these 
disease categories as well as the distribution of infections 
(pp 194–298).
Ascertainment of incident dementia after exposure to 
infection
In the primary cohort, we retrieved diagnoses of incident 
dementia from four sources: hospital inpatient records 
from the Care Register for Health Care (Finland); 
reimbursement for the treatment of dementia recorded 
by the Finnish Social Insurance Institution (these 
require verification by neurological examination, 
cognitive testing, clinical follow­up, and, for Alzheimer’s 
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disease, CT or MRI scans); causes of death recorded by 
Statistics Finland; and, in the Finnish Public Sector study 
and the Still Working study, hospital outpatient records 
from the Care Register for Health Care (appendix pp 5–7). 
The first dementia diagnosis, whether primary or 
secondary in any of these sources, defined the date of 
incident dementia.
A diagnosis of all­cause dementia consisted of the 
following ICD­10 codes: F00–F03, F05.1, G30, G31.0, 
G31.1, G31.8, and the corresponding ICD­8 (29000–29019, 
34791, 34792) and ICD­9 (290, 2900A, 2941A, 3310A, 
3311A, 3312X, 4378A) codes in the Finnish national 
editions of the ICDs. We also considered subtypes of 
dementia; Alzheimer’s disease (F00, G30, 29010, 3310A) 
versus other types of dementia further divided into 
frontotemporal dementia (G31.0, F02.0, 29011, 34791, 
3311A), Parkinson’s disease dementia (F02.3), vascular 
dementia (F01, 4378A), other specified dementia (G31.8, 
F02.1, F02.2, F02.4, F02.8), and unspecified dementia 
(F03, G31.1, F05.1, F02.39, 29000, 29019, 290, 2900A, 
2941A, 34792, 3312X).
In the replication cohort, we defined all­cause dementia 
and its subtypes (Alzheimer’s disease, vascular dementia, 
and frontotemporal dementia) using validated cohort 
algorithms (appendix p 8). For Parkinson’s disease 
dementia (F02.3) and other specified dementia (G31.8, 
F02.1, F02.2, F02.4, F02.8), we used diagnoses from 
hospital admission records as no algorithm was available. 
Unspecified dementia comprised F03, G31.1, F05.1, 
F02.39, and algorithm­based all­cause dementia without 
specified cause.
Assessment of covariates and comorbidities
Covariates included common risk factors for infection 
and dementia25–27 and comorbidities. Sex, socioeconomic 
status (low, intermediate, high), smoking (never smokers, 
ex­smokers, current smokers), and alcohol (non­drinkers, 
moderate drinkers, intermediate drinkers, and heavy 
drinkers [in the Still Working study, drinking data were 
available in three classes: non­drinkers, moderate 
drinkers, and heavy drinkers]) were considered in both 
the primary and replication cohorts at study entry. In the 
replication cohort, we additionally included body­mass 
index ([BMI] normal weight, overweight, obese) and 
apoli poprotein E genotype (none, one, or, two ε4 alleles), 
based on two single nucleotide polymorphisms (rs7412 
and rs429358) genotyped using UK BiLEVE Axiom array 
(Affymetrix; Santa Clara, CA, USA) and UK Biobank 
Axiom array (Affymetrix; Santa Clara, CA, USA).
Hypertension, diabetes, ischaemic heart disease, 
cerebro vascular disease, and Parkinson’s disease at 
baseline were considered as comorbidities potentially 
Figure 1: Classification of hospital-treated infectious diseases and the number of cases in the primary cohort
The number of cases of different infectious diseases add up to more than the total number of infection cases, because some participants were admitted to hospital for 




77 108 participants with hospital-treated infections
68 979 bacterial infections 11 335 viral infections 560 parasitic infections* 544 fungal infections (mycoses)* arasitic i fecti s
50 938 invasive bacterial infections
26 601 localised bacterial infections
4855 extracellular bacterial infections
2146 intracellular bacterial infections
3961 Gram-positive bacterial infections
3178 Gram-negative bacterial infections
580 mycobacterial infections*
239 mycoplasma infections*
7329 acute viral infections
1663 other persistent viral infections
2767 herpes virus (persistent) infections
2920 bacterial infections with sepsis
68 152 bacterial infections without sepsis
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increasing the risk of infections and dementia. These 
comorbidities were defined using primary and secondary 
diagnoses from hospital inpatient discharge information 
supplemented by reimbursement records in the primary 
cohort and measurements and self­reports in the 
replication cohort.
Exact definitions and distributions of the covariates 
and comorbidities in each cohort are provided in the 
appendix (pp 5–10).
Statistical analysis
We used Cox proportional hazards models to compute 
hazard ratios (HRs) for the associations of each infectious 
disease or disease group (index infection) with incident 
dementia. All CIs are reported at the 95% level. 
Participants with infection at or before study entry or 
during the study were considered exposed and the 
other participants with no infection were considered 
unexposed. Among the exposed, follow­up for incident 
dementia lasted from study entry or from the date of 
hospitalisation for infection to dementia diagnosis, 
death, or end of follow­up, whichever came first. To 
ensure comparable dementia follow­up between exposed 
and unexposed individuals, proportions of participants 
in the two groups were matched for those exposed before 
and after study entry within each cohort, sex, and 10­year 
age group. Follow­up for participants exposed before 
study entry commenced on entry. Follow­up for the 
remaining unexposed participants corresponded with 
the later start of follow­up in participants exposed after 
study entry.
In the primary analysis (ie, the primary cohort), we 
pooled individual­level data from the Finnish cohort 
studies and accounted for the within­study clustering of 
participants using cohort­specific baseline hazards and 
cohort­specific adjustment terms for covariates.28 We 
adjusted the analyses for sex and socioeconomic status 
and used age as the timescale. We used Wald tests to 
compute p values for differences between the dementia 
risk related to different infections. The proportional 
hazards assumption was examined using scaled 
Schoenfeld residuals (appendix pp 11, 13–15).
To reduce the risk of reverse causation and 
ascertainment bias, we repeated the analysis after 
excluding incident dementia cases that occurred during 
the first 10 years after initial hospitalisation due to the 
index infection. For those unexposed to any hospital­
treated infection, we used a similar distribution of lag­
times between study entry and start of dementia 
follow­up. We tested the interaction between time since 
infection and risk of dementia in Cox models adjusted 
for age, age squared, sex, and socioeconomic status, 
using follow­up time as the timescale. We computed 
Fine­Gray models with death and, for analysis of late­
onset dementia, also early onset dementia (dementia 
onset before 65 years) as competing risks. Furthermore, 
to test the robustness of the infection–dementia 
association, we adjusted models for smoking, 
alcohol drinking, year of birth, and, in the replication 
cohort, BMI, diabetes, hypertension, and apolipo protein 
E genotype. We repeated the analyses after excluding 
those with comorbidities (including HIV infection).
Finally, to test whether the results can be replicated 
using other statistical approaches, we repeated the main 
analyses using time­dependent Cox regression with 
infections treated as time­varying measures.
We did all data analyses using Stata MP (version 16). 
The syntax for the analyses is available in the appendix 
(pp 299–441).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results
In the primary analysis—ie, the primary cohort consisting 
of the three Finnish studies—260 490 participants were 
enrolled between March 1, 1986, and Jan 1, 2005, of whom 
153 461 (58·9%) were in the 18–39 age group when the 
dementia follow­up commenced (table). In the replication 
analysis—ie, replication cohort comprising the UK 
Biobank—a total of 485 708 participants were enrolled 
from Dec 19, 2006, to Oct 1, 2010, of whom only 
two (<0∙1%) were in the 18–39 age group when 





Age at baseline (years)
18–39 153 461 (58·9%) 2 (<0·1%)
40–49 48 221 (18·5%) 88 472 (18·2%)
50–59 34 677 (13·3%) 146 442 (30·2%)
60–87 24 131 (9·3%) 250 792 (51·6%)
Sex
Male 77 514 (29·8%) 221 026 (45·5%)
Female 182 976 (70·2%) 264 682 (54·5%)
Socioeconomic status
Low 39 878 (15·3%) 83 984 (17·3%)
Intermediate 89 258 (34·3%) 242 727 (50·0%)






Dementia by the end of follow-up
No 257 722 (98·9%) 483 576 (99·6%)
Yes 2768 (1·1%) 2132 (0·4%)





Data are n (%) or median (IQR).
Table: Baseline characteristics of the primary and replication cohorts
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replication cohort had 250 792 (51∙6%) participants 
in the 60–87 age group, compared with 24 131 (9∙3%) in 
the primary cohort. There were 182 976 (70∙2%) women in 
the primary cohort and 264 682 (54∙5%) in the replication 
cohort. The cohorts were from diverse socioeconomic 
backgrounds. In the primary analysis, 126 815 (55∙7%) of 
Figure 2: Risk of dementia associated with hospital-treated infectious diseases in the full follow-up and after 10 years or more from the onset of infection in the 
primary cohort
Error bars are 95% CIs. HRs are adjusted for sex and socioeconomic status, and age is the timescale. aHR=adjusted hazard ratio. *Difference in the association of 
bacterial and viral infections with dementia. †Difference in the association of herpes virus infections and other persistent viral infections with dementia. 
‡Difference in the association of acute viral infection and that of herpes and other persistent viral infections with dementia.
aHR (95% CI) Subgroup
difference
Total (N) Dementia (n)Exposed (n)
Full follow-up
Any infectious disease vs no infection
Bacterial infections
Any bacterial infection vs no infection
By severity
Potentially invasive bacterial infection vs no infection
Localised bacterial infection vs no infection
Bacterial infection with sepsis vs no infection
Bacterial infection without sepsis vs no infection
By location
Extracellular bacterial infection vs no infection
Intracellular bacterial infection vs no infection
By Gram stain
Gram-positive bacterial infection vs no infection
Gram-negative bacterial infection vs no infection
Viral infections
Any viral infection vs no infection
By type of viral infection
Herpes virus (persistent) infection vs no infection
Other persistent viral infection vs no infection



























































Follow-up from year 10 onwards
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the 227 673 participants were from high socioeconomic 
positions in the Finnish Public Sector study, 3876 (16∙5%) 
of 23 541 in the Health and Social Support study, and 
663 (7∙1%) of 9276 in the Still Working study; in the 
replication cohort, 158 997 (32∙7%) of 485 708 were from 
high socioeconomic positions (appendix pp 9–10).
In the primary cohort, 77 108 participants were 
hospitalised because of an infection (figure 1). Of them, 
40 145 (52∙1%) were infected at or before study entry and 
36 963 (47∙9%) developed an infection after study entry 
(incidence 922 cases per 100 000 person­years [95% CI 
912–932]). During 3 947 046 person­years at risk (median 
follow­up 15·4 years [IQR 9∙8–21∙0]), we identified 
2768 incident cases of dementia. Of these, 1730 (62∙5%) 
were diagnosed as Alzheimer’s disease, 209 (7∙6%) 
as vascular dementia, 102 (3∙7%) as frontotemporal 
dementia, 114 (4∙1%) as Parkinson’s disease dementia, 
and 613 (22∙1%) as other or unspecified dementias. We 
identified 1018 (36∙8%) of 2768 incident dementia cases 
from inpatient hospital discharge records, 786 (28∙4%) 
from other hospital records, 910 (32∙9%) from 
reimbursement for the treatment of Alzheimer’s disease 
or Parkinson’s disease dementia, and 54 (2∙0%) from 
death certificates. 2226 (80·4%) of the dementia cases 
were diagnosed at or after age 65 years (appendix p 16).
The adjusted HR (aHR) for admission to hospital for 
any infectious disease was 1·48 (95% CI 1·37–1·60) 
compared with no such hospitalisation (figure 2). 
The cumulative hazard estimate showed concurring 
evidence (appendix p 17). Associations between any 
bacterial or any viral infection and dementia were of 
comparable strength. HRs varied between 1·45 and 
2·50 for extracellular versus intracellular bacteria, Gram­
positive versus Gram­negative bacteria, invasive versus 
localised infection, status of sepsis, and type of virus 
(herpes virus vs other persistent virus vs acute 
viral infection; figure 2). Depending on infection, 
dementia incidence was 92·3 cases to 135·3 cases per 
100 000 person­years for those exposed to infection 
versus 62·8 cases per 100 000 person­years for those not 
exposed to infection when the data were standardised to 
match the age­distribution of the unexposed (appendix 
p 18). Analyses of the most common Gram­positive and 
Gram­negative infections and analyses by category 
of herpes virus infections showed no difference in 
dementia risk (appendix pp 19, 20). For herpes viruses, 
dementia risk remained increased after excluding severe 
infections (appendix p 20).
Despite an interaction between infection and follow­up 
time (aHR for interaction 0.79 [95% CI 0·74–0·85] per ln 
[time in years]), the infection–dementia association was 
not attributable to infections near the time of dementia 
diagnosis (figure 2). In analyses including only dementia 
cases that occurred more than 10 years after infection, 
Figure 3: Multivariable-adjusted associations between hospital-treated infections and dementia by dementia type in the replication cohort
Data are adjusted HRs (95% CIs), unless otherwise specified. Error bars are 95% CIs. Model 1 was adjusted for age (as the timescale), sex, and socioeconomic status. Numbers of participants, 
dementia cases, and the forest plot are for this model. Model 2 used the same adjustment criteria as model 1 and excluded participants with HIV infection; it was based on 485 453 participants 
(2131 [0·4%] with dementia) with complete information for analysis of any infection, 471 511 participants (2044 [0·4%] with dementia) for analysis of bacterial infections, and 400 502 participants 
(1322 [0·3%] with dementia) for analysis of viral infections. Model 3 used the same criteria as model 2 and additionally adjusted for alcohol drinking, smoking, body-mass index, hypertension, and 
diabetes; it was based on 480 842 participants (2080 [0·4%] with dementia) with complete information for analysis of any infection, 467 058 participants (1995 [0·4%] with dementia) for analysis 
of bacterial infections, and 397 333 participants (1304 [0·3%] with dementia) for analysis of viral infections. Model 4 used the same criteria as model 3 and additionally adjusted for apolipoprotein E 
genotype; it was based on 470 551 participants (2025 [0·4%] with dementia) with complete information for analysis of any infection, 457 104 participants (1945 [0·4%] with dementia) for analysis 
of bacterial infections, and 389 067 participants (1267 [0·3%] with dementia) for analysis of viral infections. aHR=adjusted hazard ratio. *The number of patients with dementia and viral infection 
was less than five for frontotemporal dementia and Parkinson’s disease dementia.



















































































































0·5 1 2 4 8
Increased riskDecreased risk
Articles
1564 www.thelancet.com/infection   Vol 21   November 2021
All-cause dementia (primary cohort)
Infection burden
One infection vs no infection
Two infections vs no infection
Three or more infections vs no infection
Bacterial or viral infection (but not both) vs no infection
Both bacterial and viral infection vs no infection
Number of simultaneous infections
One infection diagnosis vs no infection
Multiple simultaneous infection diagnoses vs no infection
CNS vs extra-CNS infection†
Extra-CNS infection vs no infection






































All-cause dementia (replication cohort)
Infection burden†
One infection vs no infection
Two infections vs no infection
Three or more infections vs no infection
Bacterial or viral infection (but not both) vs no infection
Both bacterial and viral infection vs no infection
Number of simultaneous infections
One infection diagnosis vs no infection
Multiple simultaneous infection diagnoses vs no infection
CNS vs extra-CNS infection
Extra-CNS infection vs no infection





































Alzheimer’s disease (replication cohort)
Infection burden†
One infection vs no infection
Two infections vs no infection
Three or more infections vs no infection
Bacterial or viral infection (but not both) vs no infection
Both bacterial and viral infection vs no infection
Number of simultaneous infections
One infection diagnosis vs no infection
Multiple simultaneous infection diagnoses vs no infection
CNS vs extra-CNS infection
Extra-CNS infection vs no infection





































Vascular dementia (replication cohort)
Infection burden†
One infection vs no infection
Two infections vs no infection
Three or more infections vs no infection
Bacterial or viral infection (but not both) vs no infection
Both bacterial and viral infection vs no infection
Number of simultaneous infections
One infection diagnosis vs no infection
Multiple simultaneous infection diagnoses vs no infection
CNS vs extra-CNS infection
Extra-CNS infection vs no infection















































0·5 1 2 4 8 16






www.thelancet.com/infection   Vol 21   November 2021 1565
HRs were significant for all infections combined 
(aHR 1·22, 95% CI 1·09–1·36), for bacterial and viral 
infections separately, and for most subtypes (figure 2). 
Infections were also associated with dementia when 
competing risk of death and early onset dementia were 
considered in the analysis (appendix p 21).
Infection was associated with an increased risk of 
Alzheimer’s disease, but associations were stronger 
for non­Alzheimer’s dementias (appendix pp 22–23). 
For example, for any hospital­treated infection, the aHR 
was 2·09 [95% CI 1·59–2·75] for vascular dementia 
versus aHR 1·20 [95% CI 1·08–1·33] for Alzheimer’s 
disease. This finding of the primary cohort was also 
observed in the replication cohort, in which 2132 patients 
with dementia were recorded over 3 172 717 person­years 
at risk (median follow­up 7·7 years [IQR 4·0–8·9]). For 
any hospital­treated infection, the strongest association 
was observed for vascular dementia (aHR 3·28 
[95% CI 2·65–4·04]), followed by Parkinson’s disease 
dementia (aHR 2∙81 [1∙67–4∙72]), frontotemporal 
dementia (aHR 1∙92 [95% CI 1∙14–3∙24]), and 
Alzheimer’s disease (aHR 1∙80 [95% CI 1∙53–2∙13]). For 
all­cause dementia, the aHR was 2·60 (95% CI 
2·38–2·83). Infections were associated with all­cause 
dementia and dementia subtypes after adjustment for 
dementia risk factors and comorbidities (age, sex, 
socioeconomic status, alcohol drinking, smoking, BMI, 
hypertension, diabetes, and apolipoprotein E genotype) 
and after exclusion of participants with HIV infection, 
ischaemic heart disease, cerebrovascular disease, and 
Parkinson’s disease (figure 3; appendix p 23).
In the primary cohort, the aHR for all­cause dementia 
was 1·41 (95% CI 1·28–1·55) for one hospital­treated 
infection versus no infection, 2·47 (2·15–2·84) for 
two hospital­treated infections versus no infection, and 
2·34 (2·03–2·69) for three or more hospital­treated 
infections versus no infection (ptrend=0·0007; figure 4). 
Corresponding aHRs in the replication cohort were 
2·15 (95% CI 1·94–2·38) for one infection versus no 
infection, 4·43 (3·82–5·14) for two infections versus no 
infection, and 7·16 (6·09–8·43) for three or more 
hospital­treated infections versus no infection. A similar 
dose­response relationship was noted for Alzheimer’s 
disease and vascular dementia in the replication cohort 
(figure 4). The increased dementia risk associated with 
multiple versus single infection at hospitalisation, 
compared with no infection, provided further support for 
a dose­response relationship. Although CNS infections 
were strongly related to all­cause dementia (aHR 3·01 
[95% CI 2·07–4·37] in the primary cohort and aHR 3·60 
[1·93–6·71] in the replication cohort) extra­CNS 
infections were also associated with an increased risk 
(1·47 [1·36–1·59] in the primary cohort and 
2·63 [2·41–2·87] in the replication cohort).
In the primary cohort, when including only dementia 
cases diagnosed at least 10 years after infection, the aHRs 
for incident dementia were 1∙12 (95% CI 0∙97–1∙29) for 
one infection, 1∙15 (0∙83–1∙60) for two infections, and 
1∙68 (1∙25–2∙25) for three or more infections; 1∙22 
(1∙09–1∙37) for bacterial or viral infection (but not 
both) and 1∙88 (1∙09–3∙26) for both bacterial and 
viral infection; 1∙21 (1∙08–1∙35) for one diagnosis 
and 1∙47 (0∙86–2∙49) for multiple simultaneous 
infection diagnoses; 1∙21 (1∙09–1∙35) for extra­CNS and 
1∙44 (0∙72–2∙89) for CNS infections. These analyses 
were not possible to repeat in the replication cohort due 
to insufficient follow­up time. In the primary cohort, the 
most common CNS infections were unspecified 
viral meningitis (n=280 [16∙9%] of 1656), unspecified 
viral infection of the CNS (n=167 [10∙1%] of 1656), 
and unspecified viral encephalitis (n=152 [9∙2%] 
of 1656); followed by unspecified bacterial meningitis 
(n=147 [8∙9%] of 1656) and enteroviral meningitis 
(n=145 [8∙8%] of 1656)]. Common extra­CNS infections 
were acute appendicitis (n=11 903 [15∙6%] of 76 301), 
unspecified pneumonia (n=6088 [8∙0%] of 76 301), other 
gastroenteritis and colitis of infectious and unspecified 
origin (n=5639 [7∙4%] of 76 301; appendix pp 252–67).
In the supplementary analyses, infection–dementia 
associations did not differ by characteristics such as 
chronicity (acute vs chronic, including periods when the 
pathogen was inactive) and capacity of the infection to 
enter the CNS (appendix p 24). Finally, all the main 
findings in both the primary and replication cohorts 
remained consistent when infections were treated as 
time­varying measures (appendix pp 25–28).
Discussion
We assessed associations between a comprehensive set 
of hospital­treated infections and dementia risk in a 
pooled analysis of about 260 000 Finnish adults followed­
up for about 15 years and about 485 000 UK Biobank 
participants followed­up for about 8 years. Those with 
infections had a 1·5­fold increased risk of dementia in 
the primary cohort and a 2·6­fold increased risk 
over the shorter follow­up in the replication cohort. 
These associations were similar for bacterial and viral 
infections and showed little specificity by type or severity 
of infection. However, there was a dose­response 
relationship between multiple episodes of hospital­
treated infection and increased dementia risk. This 
increased dementia risk was observed in sensitivity 
analyses restricted to extra­CNS infections, when reverse 
Figure 4: Risk of dementias associated with infection burden, simultaneous 
infections, and CNS vs extra-CNS infections in the primary cohort and 
replication cohort
Infections are hospital-treated. Error bars are 95% CIs. HRs are adjusted for sex 
and socioeconomic status, and age is the timescale. aHR=adjusted hazard ratio. 
NA=not applicable. *For subgroup difference. †If the participant was admitted to 
hospital several times for exactly the same diagnosis, only the first counted 
towards infection burden because the UK Biobank data included only the first 
hospitalisation for each diagnosis. ‡Fewer than five Alzheimer’s disease and 
vascular dementia cases among those exposed to CNS infections.
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causation was minimised in analyses restricted to 
infections more than 10 years before dementia onset, and 
after adjustments for comorbidities, lifestyle­related 
factors, and apolipoprotein E genotype.
Collectively, our findings suggest that systemic infla­
mmation rather than specific infections or pathogens is 
driving the development of dementia. This inference is 
supported by evidence that a range of different infectious 
diseases is associated with increased risk of cognitive 
decline and dementia7–10,22,29,30 and by investigations 
linking systemic inflammation to faster cognitive decline 
in Alzheimer’s disease.31 In animal models, progressing 
neurodegeneration has been associated with long­term 
priming of the microglia (the resident macrophages of 
the brain) to a proinflammatory state.32–34 Microglial 
priming might also be initiated by inflammatory stimuli, 
such as lipopolysaccharides produced by Gram­negative 
bacteria, and might increase the deposition of amyloid 
plaques that characterises Alzheimer’s disease.35 In 
the present study, the strongest associations between 
infection and dementia were seen for vascular dementia, 
suggesting a role for vascular mechanisms in the 
infection­related neuro pathology. Animal and in­vitro 
studies suggest that systemic inflammation can adversely 
affect brain capillaries causing blood–brain barrier 
dysfunction and related entry of neurotoxic plasma 
components, blood cells, and pathogens into the brain, a 
process leading to neuroinflammation and neuron 
loss.36–38 Blood–brain barrier dysfunction might also 
induce microbleeds and perivascular oedema, com­
promise microcirculation, and subsequently increase 
ischaemic damage.36,39
We found stronger associations between infection 
and dementia in the short term than in the long 
term. Reverse causation and ascertainment bias can 
contribute to short­term associations, but infections might 
also accelerate or exacerbate existing neuropathology.3,8,31 
Robust—albeit weaker—long­term associations, involving 
infections that occurred at least 10 years before dementia, 
suggest that infections might also trigger early stages of 
neurodegeneration. This possibility is supported by other 
studies with long­term follow­up periods,11,12 and an 
infection­dementia risk of 1·2 after exclusion of the first 
2 years of follow­up.9
We found no significant difference in dementia risk 
between acute and chronic infections. Although chronic 
infections plausibly cause a greater inflammatory 
burden than acute infections, the most common chronic 
infections tend to be milder (eg, anogenital warts, 
chronic periodontitis) than the most common acute 
infections (eg, acute appendicitis, pneumonia), 
or pri marily remain in a latent state (eg, mononucleosis).
This study has important strengths. With more than 
900 infectious diseases and about 700 000 participants, 
our study is, to our knowledge, the largest and most 
comprehensive examination of the infectious disease–
dementia association to date. Although the primary 
and replication cohorts were different, findings were 
largely consistent, supporting the generalisability of our 
observations. Our analyses of long­term associations with 
dementia minimised reverse causation and ascertainment 
biases. As disease ascertainment was from nationwide 
register data, follow­up was virtually complete and 
independent of active participation in the studies.
Limitations include potential residual confounding by 
frailty and undiagnosed comorbidities; ascertainment of 
dementia from electronic health records, which miss 
undiagnosed and milder cases;40 and a lack of information 
about biomarkers, detailed neuropathology, and infection 
treatments that might affect dementia risk. Response 
from the UK Biobank was low (503 317 [5∙5%] 
of 9 238 453).41 This effect might have contributed to 
underestimation of dementia incidence, but new 
analyses suggest close agreement between findings from 
the UK Biobank and representative UK samples for risk 
factor­disease associations.42
In conclusion, our findings support the hypothesis that 
associations between infectious diseases and dementia 
are attributable to general inflammation rather than to 
specific microbes or infections in the CNS. Our data 
also suggest that mechanisms contributing to vascular 
dementia might be particularly important drivers of the 
infection­dementia association.
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